
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is poised for substantial growth, driven by its Evernorth segment, which enhances patient satisfaction and lowers costs while also improving health outcomes. The company projects a margin recovery within its Healthcare segment, with an anticipated 100 basis points recapture by 2027, largely expected in 2026, which aligns with its long-term growth target of 7%-10% for the Healthcare segment. Additionally, Cigna's strong free cash flow will support ongoing capital deployment to expand service offerings, thereby augmenting core growth trends and reinforcing a favorable risk/reward valuation outlook.
Bears say
Cigna Group is anticipating a decline in its Evernorth adjusted operating income (AOI) for 2026, primarily due to pharmacy benefit management (PBM) margin headwinds, with estimates suggesting a drop from $3,506 million in 2025 to approximately $2,749 million in 2026. The transition to a rebate-free PBM model is projected to reduce earnings by $500 million to $600 million, further contributing to a negative financial outlook. Additional risks include potential client losses, slower biosimilar adoption, and the overall pressure on margins due to lower-priced contracts, which are likely to hinder revenue growth in a challenging commercial market.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares